Antiemetic fosnetupitant safe in breast cancer patients receiving AC/EC: study

Advances in screening and treatment for breast cancer have improved survival rates dramatically. Overall, the rate of breast cancer declined by about 40%Trusted Source between 1989 and 2017. A 2019 study showed, however, that the rate in the United States may no longer be declining in women aged 20–39 years.

In the randomized, double-blind, multicenter, phase 3, CONSOLE-BC trial, 102 patients with breast cancer treated with AC/EC chemotherapy were randomly assigned to receive either FosNTP or fosaprepitant (FosAPR), both in combination with intravenous palonosetron and dexamethasone.

The primary outcome was the incidence of treatment-related adverse events (TRAEs). The funding was given by Taiho Pharmaceutical Co., Ltd.

Key results of the study:

TRAEs were seen in 21.2% (95% CI, 11.1%-34.7%) of patients in the FosNTP group vs 22.0% (95% CI, 11.5%-36.0%) in the FosAPR group.

The frequency of TRAEs relevant to injection site reactions was 5.8% in the FosNTP group vs 26.0% in the FosAPR group.

Grade 3 or higher TRAEs occurred in 9.6% of patients in the FosNTP group vs 0% in the FosAPR group, with none resulting in death or treatment discontinuation.

Thus, Anti-emetic Fosnetupitant (FosNTP) demonstrated favorable safety, with a low risk of injection-site reactions in patients with breast cancer receiving chemotherapy with doxorubicin-cyclophosphamide or epirubicin-cyclophosphamide (AC/EC).

Reference:

Antiemetic fosnetupitant safe in breast cancer patients receiving anthracycline-cyclophosphamide by Matsuura K & al published in the Medscape.

For further reference log on to:

https://doi.org/10.1002/cncr.34088